Shares of Abbott Laboratories ABT inched 0.39% higher to $114.76 Tuesday, on what proved to be an all-around positive trading ...

Abbott Laboratories and DexCom said on Monday they have reached an agreement to settle all patent disputes between them ...

Abbott Laboratories is rated a Buy due to growth indicators, diversified portfolio, strong profit margin. Read an investment ...

Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $114.23 which represents a slight increase of $1.81 or 1.61% from the prior close of $112.42. The stock opened at $112.64 and ...

Abbott is one of the biggest healthcare companies in the world. With over 400 consecutive quarterly dividend payouts and 53 ...

A federal appeals court trimmed a whistleblower’s once-defeated False Claims Act suit Friday alleging Abbott Laboratories Inc ...

In a report released on December 20, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to ...

M&T Bank Corp lessened its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 6.3% during the 3rd quarter, ...

Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $112.42 which represents a slight increase of $0.49 or 0.44% from the prior close of $111.93. The stock opened at $111.54 and ...

The main point of investing for the long term is to make money. But more than that, you probably want to see it ...

Health care systems are making big investments in AI, and these companies are on the bleeding edge of that transition.